Entering text into the input field will update the search result below

Amgen submits Otezla plaque psoriasis marketing application to the FDA

  • Amgen (AMGN +0.3%) announced the submission of a supplemental New Drug Application ((sNDA )) to the U.S. FDA for Otezla (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.
  • The sNDA is based

Recommended For You

About AMGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AMGN--
Amgen Inc.